Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion (BRVO)

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2010 by Shaheed Beheshti Medical University.
Recruitment status was Recruiting

Sponsor:

Collaborator:

Labbafinejad Medical Center

Information provided by:

Shaheed Beheshti Medical University

ClinicalTrials.gov Identifier:

NCT01044329

First received: January 6, 2010

Last updated: NA

Last verified: January 2010

History: No changes posted

Tracking Information
First Received Date ^ICMJE	January 6, 2010
Last Updated Date	January 6, 2010
Start Date ^ICMJE	January 2010
Estimated Primary Completion Date	August 2010 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: January 6, 2010)	Visual acuity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE (submitted: January 6, 2010)	central macular thickness [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion
Official Title ^ICMJE	Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion
Brief Summary	This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 2
Study Design ^ICMJE	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment
Condition ^ICMJE	Branch Retinal Vein Occlusion
Intervention ^ICMJE	Drug: Bevacizumab Intravitreal, 1.25 mg, 3 times, one month apart. Drug: Triamcinolone Acetonide Intravitreal, 2 mg, 2 times, two months apart.
Study Arm (s)	Active Comparator: Intravitreal bevacizumab Intervention: Drug: Bevacizumab Active Comparator: Intravitreal triamcinolone Intervention: Drug: Triamcinolone Acetonide
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Recruiting
Estimated Enrollment ^ICMJE	90
Estimated Completion Date	December 2010
Estimated Primary Completion Date	August 2010 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Recent onset (less than 3 months) BRVO Exclusion Criteria: Any previous intervention
Gender	Both
Ages	Not Provided
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Not Provided
Location Countries ^ICMJE	Iran, Islamic Republic of

Administrative Information
NCT Number ^ICMJE	NCT01044329
Other Study ID Numbers ^ICMJE	8900
Has Data Monitoring Committee	Yes
Responsible Party	Alireza ramezani, Ophthamic research center
Study Sponsor ^ICMJE	Shaheed Beheshti Medical University
Collaborators ^ICMJE	Labbafinejad Medical Center
Investigators ^ICMJE	Not Provided
Information Provided By	Shaheed Beheshti Medical University
Verification Date	January 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top